Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Male Urogenital Diseases 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Genital Diseases, Male 1

Interventions

enzalutamide 10Prednisone 6Docetaxel 5Abiraterone Acetate 4darolutamide 3olaparib 2niraparib 2abiraterone 2Pluvicto 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1radium Ra 223 dichloride 1quemliclustat 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1Nivolumab 1JNJ-64619178 1JNJ-64264681 1Ipilimumab 1Gonadotropin-Releasing Hormone 1Dexamethasone 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × gedatolisib × 1 year × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡